BMY

Bristol-Myers SquibbC

NYSE / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment AI

B+

Bull case

20%

Probability

Target price

$68.00

+24.9% vs current

Most likely

Base case

60%

Probability

Target price

$57.68

+5.9% vs current

B-

Bear case

20%

Probability

Target price

$37.00

-32.1% vs current

AI sentiment snapshot

Latest data as of 2026-02-06

AI commentary

Market consensus is broadly neutral-to-slightly-bearish with median targets near $57.68 while the anchor price trades at $59.51, indicating limited upside in the near term [#SERP-8] [#SERP-4]. Coverage shows a wide spread between low and high analyst views, reflecting binary pipeline and litigation risks [#SERP-3].

RankAlpha Sentiment AI - 2026-02-06

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-07catalystQuarterly earnings and updated 2026 guidanceMedium impact

Q4/FY2025 earnings release and management guidance update; market reaction likely if EPS/revenue or guidance diverges from consensus [#SERP-4]. Date conservatively estimated to allow filings and call prep.

2026-12-31eventLate-stage clinical readout / regulatory milestone (assumed window end)High impact

Potential Phase III readout or regulatory decision for a late-stage oncology/immunology asset; date uses conservative window end assumption and may move shares materially if outcome differs from expectations [#SERP-1]. Assumed window end for planning.

2027-02-06catalystPatent, litigation or portfolio M&A developmentsHigh impact

Potential litigation outcomes, biosimilar decisions, or strategic M&A that could re-rate valuation over a multi-quarter horizon; date set conservatively one year out [#SERP-2].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-02-06 • Updated nightlySource: Internal modelMethodology